MGMT immunohistochemistry (IHC) and exclusion of pancreatic NET (PanNET) patients from treatment with temozolomide-based therapy.

e15169 Background: Predictive markers are needed for improved selection of patients for Capecitabine/Temozolomide (C/T) therapy in metastatic PanNETs. Treatment efficacy has been reported to correl...